We know from previous work that baseline CD4+ TEM expansion is only a useful biomarker of hepatitis risk in CMV-seropositive patients, who constituted just 47.3% of our study cohort; therefore, this is a biologically validated example of alternative immunopathologies contributing to a common pathological presentation that impacts biomarker performance. This evidence concerns the gene CD4 and hepatitis A virus infection.